Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful completion of ‘proof of concept’ of its
A cannabinoid drug company has opted to undertake its trials in America due to the complexities of the UK’s licensing regime.
Chill Brands The CBD and vaping retailer Chill Brands has voted to oust two of its longest-standing directors as
Last week, UK biotechnology firm Oxford Cannabinoid Technologies (OCT), one of the first cannabis companies in history to list on
Synbiotic German cannabis group SynBiotic has capitalised on the recent explosion in medical cannabis patients since the country’s landmark
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a
MGC Pharmaceuticals / Argent BioPharma MGC Pharmaceuticals has become the latest UK-listed cannabis company to opt for a rebrand
Cellular Goods (Cel AI) Cellular Goods has this morning announced another major pivot in its strategy, just days after
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
